Breakfast Symposium: Making the Switch: The Use of Biosimilars in IBD Management

Breakfast Symposium: Making the Switch: The Use of Biosimilars in IBD Management

National Meeting
Program Details

Registration for the symposium is now available. 

A Saturday Satellite Symposium: Advances in Inflammatory Bowel Diseases Congress 2019

Walt Disney World Swan and Dolphin Resort
Meeting Room:  Northern Hemisphere A

Orlando, Florida

December 14, 2019

6:00 AM - 6:30 AM, Registration and Complimentary Lunch Buffet
6:30 AM - 7:45 AM, Interactive Symposium and Q&A Session



Raymond K. Cross, MD, MS, AGAF, FACG
University of Maryland School of Medicine
Lutherville, Maryland


Marla C. Dubinsky, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Alan C. Moss, MD, FACG
Boston, Massachusetts

Intended Learners

Designed and certified for the entire IBD healthcare team and includes education for gastroenterologists, pediatric gastroenterologists, surgeons, physicians, PhDs, researchers, pharmacists, nurse practitioners, physician assistants, gastroenterology nurses, and residents/fellows/students.

Learning Objectives

After participating in this activity, learners should be able to:

  • Discuss the biosimilar regulatory review process and the characteristics of biosimilars as compared to their originator biologics
  • Review the most recent safety, efficacy, and switching data for current and emerging biosimilars in IBD
  • Develop personalized treatment plans that incorporate biosimilars into IBD management where appropriate and include strategies for patient education
Activity Overview

Participants will obtain a pre- and post-activity survey, evaluation, and activity materials onsite. Attendees will be asked to complete the pre-activity survey before the lecture and the post-activity survey and evaluation immediately after the lecture. A faculty question-and-answer session will follow the presentation.

Instructions for Receiving Documentation of Credit

Participants are requested to complete the electronic evaluation immediately following the educational session or complete the online evaluation within 2 weeks of the event. Participants who submit an electronic evaluation onsite will receive documentation of credit via email within 8 weeks. Individuals who participate in the activity and submit the evaluation form online at will immediately receive documentation of credit.  Participants will be asked to log in or create an account at


 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


 Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Imedex designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 1 contact hour.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour. 


This live, knowledge-based activity (Universal Activity Number JA0006201-9999-19-183-L01-P) has been approved for a maximum of 1 contact hour (0.01 CEU).  

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is January 12, 2020 (60 DAYS AFTER ACTIVITY.) Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation 

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance,  by phone at 609-371-1137, by email  at or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.  The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell,  Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009.

ADA Statement

Imedex, an HMP Company complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137. 

Planning Committee

The planning committee comprises of Raymond K. Cross, MD, MS, AGAF, FACG; Marla Dubinsky, MD; and Alan C. Moss, MD, FACG

Imedex planners and staff include Chris Bolwell and Kelly Jackson.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty is reported the following:

Raymond K. Cross, MD, MS, AGAF, FACG reports being a Consultant for Abbvie; Gilead; LabCorp; Janssen; Pfizer and Takeda; and Grant/Research Support for Abbvie

Marla C. Dubinsky, MD reports being a Consultant for Abbvie, Janssen, Takeda, Pfizer, Celgene, Arena, Genentech, UCB, Salix, Prometheus, Lilly, BMS, Gilead and Boeringher Ingelheim; Grant/Research Support for Pfizer, Prometheus, Abbvie and Janssen; as well as Co-Founder Mi Test Health and Cornerstones Health

Alan C. Moss, MD, FACG reports being a Consultant for Janssen; and Grant/Research Support for Pfizer

Chris Bolwell  is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to

Grant Support

This activity has been supported through an independent educational grant from Merck Sharp & Dohme Corp. and Samsung Bioepis Co., Ltd

Privacy Policy

Imedex protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Imedex and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.